Pancreatic ductal adenocarcinoma (PDAC) is characterized by extensive stroma and pathogenic modifications to the peripheral nervous system that elevate metastatic capacity. In this study, we show that the IL-6-related stem cell promoting factor LIF supports PDACassociated neural remodeling (PANR). LIF was overexpressed in tumor tissue compared to healthy pancreas, but its receptors LIFR and gp130 were expressed only in intratumoral 
Abstract:
Pancreatic ductal adenocarcinoma (PDAC) is characterized by extensive stroma and pathogenic modifications to the peripheral nervous system that elevate metastatic capacity. In this study, we show that the IL-6-related stem cell promoting factor LIF supports PDACassociated neural remodeling (PANR). LIF was overexpressed in tumor tissue compared to healthy pancreas, but its receptors LIFR and gp130 were expressed only in intratumoral nerves. Cancer cells and stromal cells in PDAC tissues both expressed LIF, but only stromal cells could secrete it. Biological investigations showed that LIF promoted the differentiation of glial nerve sheath Schwann cells and induced their migration by activating JAK/STAT3/AKT signaling. LIF also induced neuronal plasticity in dorsal root ganglia neurons by increasing the number of neurites and the soma area. Notably, injection of LIFblocking antibody into PDAC-bearing mice reduced intratumoral nerve density, supporting a critical role for LIF function in PANR. In serum from human PDAC patients and mouse models of PDAC, we found that LIF titers positively correlated with intratumoral nerve density. Taken together, our findings suggest LIF as a candidate serum biomarker and diagnostic tool and a possible therapeutic target for limiting the impact of PANR in PDAC pathophysiology and metastatic progression.
Introduction:
Pancreatic ductal adenocarcinoma (PDA) is considered as one of the most serious cancers, with a quick and asymptomatic evolution leading to a very low survival rate in patients (1, 2) Even with recent improvements (3), current treatments, mainly based on surgery and chemotherapies, have a limited impact on the patient's fate, in part due to impaired drug perfusion provoked by the stromal reaction surrounding tumor cells (4, 5) . Indeed, PDA is characterized by the presence of a predominant stroma (intra-tumoral microenvironment) composed of cancer associated fibroblasts (CAFs), immune, endothelial and nerve cells.
These have all been reported as drastic modifiers of tumor cells' abilities thereby impacting on pancreatic tumor evolution and prognosis (6) . However, recent advances based on the effects of the stromal compartment on PDA are limited, and their clinical translation remains difficult (7) .
In addition to evidence showing the major implication of the stroma in PDA evolution and in therapeutic resistance, several studies have highlighted profound alterations of the neural compartment and its concrete impact on patient's fate and quality of life (8, 9) . These alterations, called PDA associated neural remodeling (PANR), result in higher nerve densities in PDA due to peripheral nerve fibers infiltration and axonogenesis (10, 11) . Recently, we highlighted, in a previous study, that the intra-tumoral microenvironment could be a cause of those profound alterations (12) . Thus, deciphering the specific connection between stromal compartment and nerve system in PDA could uncover potential therapeutic targets and clinical tools that would limit the nervous system-related impact on PDA evolution that alter patients' fate (13, 14) .
Indeed, a direct consequence of this neural remodeling in PDA is the appearance of perineural invasion (PNI) events, marked by the cancer cell's capacity to invade pancreatic nerves present within the tumor (15, 16) . In PDA, PNI is considered as an indicator of an aggressive Author Manuscript Published OnlineFirst on December 21, 2017; DOI: 10.1158/0008-5472. CAN-15-2790 tumor associated with local recurrence and metastasis, acute neuropathic pain and leading to bad prognosis (8, 17, 18) . Interestingly, recent reports have highlighted the role of the intratumoral microenvironment (19, 20) , and inflammatory processes (21) as pro-inflammatory cytokines like IL-6,(22) in PANR. Despite this, molecular mechanisms allowing neural remodeling and PNI events in PDA remain poorly understood. Thus, in-depth molecular studies are required to improve our knowledge in this field, which could provide new therapeutic opportunities to impair PDA progression and associated symptoms that limit patients' access to chemotherapy (23,24) and negatively influence their outcome.
Here we demonstrate, in human and mice, that LIF has a direct role on PDA Associated Neural Remodeling. We observed that, within PDA, stromal cells, mainly macrophages and fibroblasts, have the ability to secrete LIF acting then on pancreatic neural compartment.
Indeed, LIF can induce migration and differentiation of Schwann cells and neural plasticity of dorsal root ganglia (DRG) neurons through modulation of the JAK/STAT3 intracellular signaling. Using endogenous mice model of PDA treated with LIF-blocking antibody, we revealed that LIF is important for PANR. In addition, high levels of LIF were detected in sera from humans and mice with PDA but not that from healthy individuals or patients with benign pancreatic diseases. Altogether, our data suggest that LIF is a potent biomarker for the diagnosis of PDA, and that the therapeutic targeting of LIF-induced signaling in PDA could limit PANR and improve patient outcome and quality of life.
Research. 
Materials and Methods

Cell lines
Human samples
Chronic pancreatitis (31 samples), pancreatic benign tumor (11 samples) 
Murine serum and samples
Sera from healthy and PDA bearing mice were obtained after intra-cardiac puncture and separation between plasma and blood cells by centrifugation. Mice developing PDA were euthanized when they were moribund (average of 8.5 weeks old). To obtain sera from chronic pancreatitis in mice, caerulein (50μg/kg/100μl) was injected twice a week for 10 week by intraperitoneal way (p.i). Sera from acute pancreatitis was obtained after 6 successive hourly injections by p.i. All animal care and experimental procedures were performed following approval by the Animal Ethics Committee of Marseille.
Statistical Analysis
The results showed are averages or medians, and error bars in graphs represent standard deviations (SD). The Mann-Whitney test, recommended for the comparison of two independent groups, was performed when required. The Wilcoxon test was used, when required, to analyze two different parameters within an experimental group. Differences were considered significant if P was less than 0.05. All P values were calculated using the Graphpad prism software. All experiments were repeated at least 3 times. LIF and IL-6
Research. concentrations were transformed using a lin-log function (namely arc-sinus-hyperbolic) and scaled in order to cover the same range. Combining markers was carried out by the estimation of a logistic model. The rms package allowed logistic regression and models comparison.
Results:
Members of the gp130 "ligand/receptor" family are overexpressed in human and murine PDA
We previously showed that the stromal compartment can, through its secretory ability, impact nerve system reorganization within PDA tumors (12) . Regarding recent studies revealing a role of inflammatory processes in PANR (11, 22) , we hypothesized that some genes/pathways, involved in the regulation of inflammatory processes, may be upregulated in the stromal compartment of pancreatic cancer and could impact PANR. Using two sets of RNA microarray analysis previously published by our group (Gene Expression Omnibus (GEO): GSE50570 for human PDA, (12) , and GSE61412 for mouse PDA, (27)), we revealed that numerous members of the gp130 "ligand/receptor" family, with some already associated with neuropathic disorders or regulation of the nervous system ( the two LIF receptors, LIFR and gp130 ( Fig. 1A and D) . Indeed, LIFR proteins were present in 8 out of 12 nerves analyzed within PDA tumors with a mean expression of 9.7% inside nerves. In addition, gp130 was found in 4 out of 12 nerves but with a stronger mean expression (20%). These changes in LIF expression were confirmed in PDA mouse model with a strong increase in LIF mRNA (Fig. 1E) and protein ( Fig. 1F and 1G ) level in PDA samples compared to healthy pancreas. Altogether, these data reveal the presence of LIF and its receptors, LIFR and gp130, in PDA samples. Moreover, the expression patterns of LIFR and gp130 support the hypothesis of LIF implication in PDA associated neural remodeling.
In PDA, secretion of LIF is mediated by the stromal compartment in vitro and in vivo
Regarding above data, we next sought to determine which cell types within PDA produced LIF. Using TMA of various human PDA samples, we observed that few epithelial cancer cells (cytokeratin-19) expressed LIF whereas higher percentages of macrophages (CD68), CAFs ( SMA) and mast cells (CD117) were labeled with LIF staining (Fig. 2A ).Such analysis on 8 different human PDA showed that only 6% of cancer cells expressed LIF whereas mast cells, macrophages and CAF expressed LIF at 21%, 34% and 47,5% respectively. This was confirmed by measurement of LIF mRNA expression in vitro, where fibroblasts (FHN) expressed higher amount of LIF mRNA than macrophages (RAW) or mast cells (HMC-1) ( fig. 2B) . Interestingly, when co-cultured with RAW or HMC-1 or RAW+HMC-1, the fibroblasts showed an increased LIF mRNA expression (Fig. 2B ). This level of LIF mRNA expression is similar with the one observed in primary CAFs from PDA patients ( Supplementary Fig. 1 ). This data suggests, as shown previously (11) , that FHN co-cultivated with RAW reach a similar threshold of activation than primary CAFs. revealed that stromal cells express the highest amount of LIF mRNA (Fig. 2C) . Surprisingly, the increased level of LIF mRNA in PDA co-cultured stromal cells did not result in higher LIF protein levels compared to single stromal or tumoral cell cultures ( Fig. 2D and E).
Considering this discrepancy between mRNA production and intracellular protein levels, we hypothesized that there was a change either in translation machinery, in LIF degradation or in LIF secretion. As LIF is referenced as a secreted cytokine, we measured by ELISA the amount of LIF secreted in media and observed a higher LIF concentration in media from fibroblasts co-cultured with macrophages compared to other stromal cell cultures ( Fig. 2F and supplementary Fig. 2A ). Interestingly, whereas amount of LIF secreted by CAF was higher than by FHN, we observed that amounts of LIF secreted were not different between CAF and FHN when co-cultured with RAW. Importantly, LIF was either undetectable or present in small amount in media from various tumor cells (Fig. 2G) . Altogether, these data revealed that while numerous cell types within PDA potentially express LIF, the ability to secrete it seems restricted to the stromal compartment and in particular mostly to activated fibroblasts, a major cell component of PDA microenvironment that we have recently linked to PANR (12) .
LIF enhances the migratory capacity of peripheral nerve Schwann cells
We sought to determine if the presence of secreted LIF in PDA could modulate nerve cells' abilities, and therefore have an impact on PANR. We investigated the effect of stromal conditioned media (CM) with the highest LIF titer (FHN+RAW and FHN+RAW+HMC1) on the migratory ability of peripheral nerve Schwann cells and we observed a two-fold increase of Schwann cell migration after 4h ( Fig. 3A and supplementary Fig. 2B ). To assess whether LIF from those stromal CM was the mediator of the observed migratory improvement, we blocked LIFR and consequently impaired LIF signaling with a blocking LIFR antibody (Ab-LIFR) and observed that migration ability is restored to control level ( signaling, the specific pathway activated after gp130/LIFR induction (32,33), respectively, confirmed previous data (Fig. 3C) . Finally, LIF's specific ability to enhance the migration of peripheral nerve Schwann cells was confirmed with human recombinant LIF protein at a dose of 50ng/ml, determined as the lowest dose inducing the higher migration improvement (Fig.   3D ). Such induced migration ability with LIF recombinant protein was inhibited using LIFR blocking antibody at the lower dose of 4μg/ml ( Fig. 3A and 3B). We further confirmed that such signaling activation is mediated by LIF receptors, LIFR and gp130, as AG490 or LIFR blocking antibody were able to inhibit STAT3 and AKT phosphorylation ( Supplementary Fig. 3C ). As reported in Figure   3G , stromal cells CM could induce STAT3 or AKT phosphorylation/activation. However, the use of AG490 or LIFR blocking antibody inhibited stromal cells CM effects on intra-cellular signaling suggesting that the CM-derived LIF could no longer activate LIFR/gp130 signaling.
Altogether, our results revealed that LIF from stromal cell conditioned media is able to induce Schwann cell migration through LIFR/gp130 signaling then STAT3/AKT phosphorylation/activation.
LIF inhibits Schwann cell proliferation
Research. Fig. 4A ). We validated that this decreased cell proliferation was due to the presence of LIF by adding the LIFR blocking antibody to the CM, which restored cell proliferation to the control level (Fig. 4B) . We obtained similar results using LIF recombinant protein with a cell growth reduction of about 17% (Fig. 4C ) without modification of cell survival ( Supplementary Fig. 4B ).
In agreement with previous report linking JAK/STAT3 pathway activation and cell growth arrest (35), we observed an increase in p21 mRNA level by 24 hours post-LIF treatment ( Fig.   4D ) and an increase in p21 protein level by 36 and 48 hours (Fig. 4E ). Interestingly, p21
protein level is restored with AG490 or SC144 treatments on cells incubated with LIF recombinant protein (Fig. 4F) or with stromal cells CM (Fig. 4G ). These data highlight the impact of LIF secreted by PDA stromal cells on the reduction of Schwann cell proliferation, which occurs concordantly with their enhanced migratory abilities.
LIF induces Schwann cell differentiation and neuronal plasticity
Interestingly, JAK/STAT3 pathway is known to induce cell differentiation, a crucial process for nerve cells involved in PANR. Thus, we analyzed Pou3F2 and S100, two independent markers of Schwann cell differentiation (36,37) that we found expressed in human PDA nerve fibers ( Supplementary Fig. 5A ). Interestingly, we observed an induction of both markers in Schwann cells after 48 hours of incubation with stromal cell CM ( Fig. 5A and 5B, left panels). Such increased was lost when stromal cells CM was supplemented either with LIFR blocking antibody ( Fig. 5A and 5B, right panels), AG490 or SC144 (Supplementary Fig. 5B ).
Moreover, we showed that incubation with LIF recombinant protein was able to induce Pou3F2 and S100 expression in Schwann cells at both mRNA (Fig. 5C ) and protein levels ( Fig. 5D and 5E ). Besides its impact on Schwann cells, we wondered whether LIF may affect neuronal plasticity associated to PANR (38). As suspected, we found that recombinant LIF could induce neuronal plasticity with increased neurite outgrowth (Fig. 5F ) and soma area (Fig. 5G) . Those data reveal that LIF, secreted by PDA stromal cells, is able to induce Schwann cell differentiation and neuronal plasticity. In addition to data shown in previous parts, our study firmly support the potent impact of LIF in the neural remodeling observed in PDA tumors.
LIF titer in serum as a diagnostic and prognostic biomarker for PDA patients
To definitively assess if LIF is an inductor of PANR in vivo, we first analyzed LIF titer in sera from PDA bearing mice compared to LIF titer in sera from healthy mice and mice developing acute or chronic pancreatitis. Interestingly, not only we found a significant increase in LIF titer sera in PDA-bearing mice compared to control or benign pancreatic diseases (Fig. 6A) but we found that LIF titer in sera from PDA-bearing mice is positively correlated with intratumoral nerve density (R2=0.82, n=12, Fig. 6B ). Finally, we assessed in vivo if LIF was directly influencing intra-tumoral nerve density by using a LIF neutralizing antibody in mice developing PDA. As shown in figure 6C, control mice (treated with a control antibody) displaying a low level of LIF in serum (<124pg/ml) exhibit few intra-tumoral nerves while control mice displaying a higher level of LIF in serum (>124pg/ml) showed a significant increase in the intra-tumoral nerve density. Interestingly, mice treated with the LIF neutralizing antibody showed a significant reduction of intra-tumoral nerves in spite of the presence of a high LIF quantity in serum (>124pg/ml). Those data revealed that LIF is directly enhancing intra-tumoral nerve density in PDA and that LIF titration in serum could serve as a biomarker to predict PANR. Using a cohort including human sera from healthy donors (N=61), patients with chronic pancreatitis (N= 31) or benign pancreatic tumor (N=11) with cystic adenomas and IPMN (Intraductal Papillary Mucinous neoplams) and PDA patients (N=142), we confirmed previous mice data (Fig. 6A ) and showed that LIF titer was only increased in sera from PDA patients compared to other groups (Fig. 6D) . Also we confirmed in sera from PDA patients the positive correlation between LIF titer and intra-PDA nerve density (R 2 =0.74, n=10, Fig.   6E ). Above data suggest that LIF titer in serum is associated to PANR and could help in classifying PDA patients in terms of PANR grade.
Altogether, these data support the use of LIF titer as a diagnostic marker for all stages pancreatic cancer and as a biomarker to discriminate PANR level in PDA patients.
Discussion
Considering the grim mean survival rate among pancreatic cancer patients as well as the limited improvement of clinicians' arsenal over the last twenty years, it has become urgent to explore new therapeutic avenues that target PDA evolution as well as PDA-associated phenotypes. Among the latter, neuropathic pain and cachexia are major problems; management of these symptoms is fraught with difficulties, and globally, there exists no agreed upon standard care or treatment. Importantly, both symptoms are often the determining factors in deciding between patients' eligibility for chemotherapy or palliative care. Among fields to explore in order to improve drug accessibility and maintenance of treatment in PDA patients, deciphering mechanisms underlying PDA associated neural remodeling could yield promising results.
Although clinicians have for many years reported nervous system reorganization in cancers, and specifically in PDA, fundamental researchers have only recently realized its possible implications in PDA evolution and patient survival (8, 13) . It is now well acknowledged that infiltration of the tumor microenvironment by nerves, termed neoneurogenesis or axonogenesis, which occurs early in PDA development (11) , plays an active role in cancer progression (39) and correlates with shortened survival, pain and local tumor recurrence (8) .
Although several studies have reported the ability of cancer cells to attract nerve fibers (40, 41) , very few have reported the impact of stromal cells in this process (12) , especially in PDA where stromal cells compose the vast majority of the tumor cell mass. Therefore, our goal was to identify molecular targets from the PDA microenvironment that are involved in PANR, which may lead to the discovery of potent future adjuvant therapies that could prolong survival and reduce morbidity by blocking PANR. Here, we demonstrated for the first time that LIF, secreted by the PDA microenvironment, induced nerve cell migration and differentiation and thereby is positively correlated with PANR and axonogenesis (Fig. 6F) .
Concomitantly, we have revealed that LIF is a potent biomarker for PDA and helps in determining PANR in PDA.
In this study, we considered knowledge associating tumor inflammation both with pancreatic cancer (42) and with the modulation of the nerve compartment (43, 44) to reach our hypothesis that stromal-driven inflammatory genes/pathways could, additionally to their effects on tumor cells, impact the nerve compartment and in particular PANR. Thus, we revisited previous transcriptomic analysis (Gene Expression Omnibus (GEO): GSE50570 for human PDA, (12) , and GSE61412 for mouse PDA, (27) and highlighted numerous genes that code for molecules involved in gp130 signaling and were overexpressed in the PDA stromal compartment compared to PDA tumor cells.
Among, the identified gp130-related genes, we focused on LIF due to its major role in regulating the nervous system (45) . Indeed, very little is known of its potent role in this context except a study suggesting that increased levels of LIF in PDA could impact the STAT3 pathway in cancer cells (31). In addition to confirming these results in both human and mouse PDA, our study has extended our knowledge on LIF from its expression pattern to its mode of secretion within PDA, revealing that although both tumor and stromal cells (CAFs, mast cells and macrophages) were able to express LIF, only stromal cells could secrete it. This striking and somewhat unexpected result reinforces the potent role of the stromal compartment in PANR but also raises questions about the role of this non-secreted LIF within PDA cancer cells. In our study we were interested in the effect of the stromal cellsecreted LIF in human PDA and found that infiltrating nerve fibers expressed LIFR and gp130 indicating a possible triggering of LIF signaling within these nerve cells.
We extended our in vivo data with in vitro experiments performing heterotypic co-cultures of stromal cells. We observed that co-cultures with macrophages drastically enhanced LIF secretion by fibroblasts, which is consistent with recent findings concerning LIF expression by activated fibroblasts (46) . Here, we demonstrated that LIF is a strong modulator of nerve cell status, in terms of motility, proliferation and differentiation. Interestingly, this part of the study is highly similar with our previous study about the stromal-derived SLIT2 impact on PANR (12). Indeed we mentioned in this work the ability of CAF-derived SLIT2 to induce PANR in PDA. While the relevance of SLIT2 as an efficient biomarker was not reported, the connection between SLIT2 and LIF and their possible association to a further common signaling pathway should be investigate in order to determine if SLIT2/LIF-impact on PANR However, while we had demonstrated that LIF could modulate nerve cell status in vitro and backed this up by revealing a plausible cellular expression of LIF, LIFR and gp130 in human PDA, we needed a correlation between the presence of LIF in PDA patients and PANR. Therefore, we measured LIF titer in serum from human or mouse PDA and correlated it with the nerve density in the corresponding PDA sample. In both models, we found a positive correlation between the amount of LIF in the serum and the intra-tumoral nerve density, supporting a link between LIF and PANR as well as revealing LIF as a valuable biomarker to determine PANR level in PDA. In addition to confirming our hypothesis, we observed that LIF titration in serum from PDA patients could have other uses. Indeed, as already reported for IL-6 and IL-11, cytokine serum levels are valuable diagnostic and prognostic tools (47) (48) (49) . The specificity given by LIF to distinguish PDA from other benign pancreatic diseases [282036].
Research. Quantifications noted are expressed as fold changes compared with H1. Each experiment was reproduced at least three times. *, P < 0.05; **, P < 0.01. 
Quantifications noted are expressed as fold changes compared to macrophages (Raw) or fibroblasts (CAF). E, LIF immunoblots. Quantifications noted are expressed as fold changes compared to fibroblasts co-cultivated with macrophages (FHN+RAW). F, Quantification of secreted LIF, by ELISA assay, in various stromal cells conditioned media (mean ± SD). This experiment was reproduced 4 times, using 4 different CAFs. G, Quantification of secreted LIF, by ELISA assay, in conditioned media from stromal and tumor cells (mean ± SD). Each experiment was reproduced at least three times. *, P < 0.05; **, P < 0.01. with AG490 (F and G) or SC144 (F) treatments. Each experiment was reproduced at least three times. *, P < 0.05. and Pou3F2 immunoblots in sNF96.2 cultured as in (A). C, S100 and Pou3F2 mRNA expression levels in sNF96.2 cells incubated with 50ng/ml of LIF recombinant protein (mean ± SD). D, Representative images of Pou3F2 and S100 dual-staining on sNF96.2 cells incubated with 50ng/ml of LIF for 48 hours (bars, 100μm). E, S100 and Pou3F2 immunoblots from sNF96.2 cells incubated for 48 hours with LIF (50ng/ml). F and G, Effects of 50ng/ml of LIF (24 and 48 hrs) on neuronal plasticity (F, neurite number and G, soma area) of neurons from DRG (mean ± SD). Each experiment was reproduced at least three times. *, P < 0.05. 
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